• +1-646-491-9876
    • +91-20-67278686

    Search

    Fibroblast Growth Factor Receptor 4-Pipeline Review H1 2017

    Fibroblast Growth Factor Receptor 4-Pipeline Review H1 2017

    • Report Code ID: RW0001834445
    • Category Pharmaceuticals
    • No. of Pages 103
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H1 2017

    Summary

    Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Fibroblast Growth Factor Receptor 4 - Pipeline Review, H1 2017, outlays comprehensive information on the Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type.

    Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Fibroblast growth factor receptor 4 is a protein encoded by the FGFR4 gene. It plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. It is required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. It phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades. The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 10, 5, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Metabolic Disorders, Gastrointestinal, Central Nervous System and Musculoskeletal Disorders which include indications Hepatocellular Carcinoma, Solid Tumor, Bile Duct Cancer (Cholangiocarcinoma) , Type 2 Diabetes, Breast Cancer, Esophageal Cancer, Gastric Cancer, Lung Adenocarcinoma, Lymphoma, Melanoma, Non-Alcoholic Steatohepatitis (NASH) , Non-Small Cell Lung Cancer, Obesity, Ovarian Cancer, Recurrent Glioblastoma Multiforme (GBM) , Adrenocortical Carcinoma (Adrenal Cortex Cancer) , Chronic Lymphocytic Leukemia (CLL) , Constipation, Endometrial Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Fibrosis, Glioblastoma Multiforme (GBM) , Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Metastatic Biliary Tract Cancer, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Nasopharyngeal Cancer, Non-Small Cell Lung Carcinoma, Osteosarcoma, Peritoneal Cancer, Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis, Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Small-Cell Lung Cancer, Spinal Cord Injury, Thymic Carcinoma, Thyroid Cancer and Transitional Cell Cancer (Urothelial Cell Cancer) .

    Furthermore, this report also reviewsalso reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)
    - The report reviews Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Overview
    Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
    Amgen Inc
    ArQule Inc
    Astellas Pharma Inc
    AstraZeneca Plc
    Blueprint Medicines Corp
    Bristol-Myers Squibb Company
    Eisai Co Ltd
    Eli Lilly and Company
    Genosco Inc
    H3 Biomedicine Inc
    Incyte Corp
    Ionis Pharmaceuticals Inc
    Johnson & Johnson
    NGM Biopharmaceuticals Inc
    Novartis AG
    Principia Biopharma Inc
    Tasly Pharmaceutical Group Co Ltd
    Vichem Chemie Research Ltd
    Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Drug Profiles
    ARQ-087 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ASP-5878 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AZ-709 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BLU-554 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BLU-9931 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BMS-986036 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    erdafitinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ES-135 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    FGF-401 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    golvatinib tartrate + lenvatinib mesylate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    H-3B6527 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    INCB-62079 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    infigratinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IONIS-463588 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    lenvatinib mesylate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LY-2874455 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NGM-282 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PRN-1371 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Protein 1 to Agonize Fibroblast Growth Factor Receptor for Fibrosis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Protein to Agonize FGFR for Type 2 Diabetes - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Antagonize FGFR4 for Hepatocellular Carcinoma - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Pan FGFR for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TSLB-1344 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Dormant Products
    Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Discontinued Products
    Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Product Development Milestones
    Featured News & Press Releases
    Jun 05, 2017: Eisai to Present Results of Phase Ib/II Study of Anticancer Agent Lenvima (Lenvatinib) in Combination With Anti-PD-1 Antibody Pembrolizumab for the Treatment of Endometrial Carcinoma at 53rd ASCO Annual Meeting
    Jun 05, 2017: Eisai to Present Results of Phase III Trial of Lenvima (Lenvatinib) as First-line Treatment for Unresectable Hepatocellular Carcinoma in Oral Session at 53rd Asco Annual Meeting
    May 18, 2017: Eisai to Present Abstracts on Lenvatinib At 53rd ASCO Annual Meeting
    May 17, 2017: ArQule to Present Clinical Data on ARQ-087 at the 2017 American Society of Clinical Oncology Annual Meeting
    Apr 22, 2017: Bristol-Myers Squibb's BMS-986036 (Pegylated FGF21) Shows Consistent Improvement in Liver Fat, Liver Injury and Fibrosis in Patients with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial
    Apr 22, 2017: NGM Bio Announces NGM282 Dramatically Reduced Liver Fat and Other Biomarkers Associated with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial
    Apr 05, 2017: Eisai Presents Data Of Mechanisms Of Action Relating To Tumor Immune Response Regarding Combination Of Anticancer Agent Lenvatinib With Anti-PD-1 Antibody At AACR 108th Annual Meeting
    Apr 05, 2017: NGM Bio to Present Phase 2 Data of NGM282 in NASH at International Liver Congress 2017
    Mar 28, 2017: Eisai to Present Data on Lenvima at 2017 AACR Annual Meeting
    Mar 28, 2017: German Federal Joint Committee (G-BA) Confirms Additional Benefit of Kisplyx (lenvatinib) in Treatment of Advanced Renal Cell Carcinoma
    Mar 27, 2017: Blueprint Medicines to Present on BLU-554 at Upcoming Scientific Conferences
    Mar 23, 2017: Mass. General team identifies mechanisms behind resistance to FGFR inhibitor drug
    Mar 09, 2017: H3 Biomedicine to Present on H3B-6527 at 2017 American Association of Cancer Research Annual Meeting
    Jan 25, 2017: Phase III Trial Of Anticancer Agent Lenvima As First-Line Treatment For Unresectable Hepatocellular Carcinoma Meets Primary Endpoint
    Jan 04, 2017: German Institute for Quality and Efficiency in Health Care Confirms Additional Benefit for Kisplyx (lenvatinib) in Combination with everolimus for the Treatment of Advanced Renal Cell Carcinoma
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indications, H1 2017
    Number of Products under Development by Indications, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Indications, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Number of Products under Investigation by Universities/Institutes, H1 2017
    Products under Investigation by Universities/Institutes, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by Amgen Inc, H1 2017
    Pipeline by ArQule Inc, H1 2017
    Pipeline by Astellas Pharma Inc, H1 2017
    Pipeline by AstraZeneca Plc, H1 2017
    Pipeline by Blueprint Medicines Corp, H1 2017
    Pipeline by Bristol-Myers Squibb Company, H1 2017
    Pipeline by Eisai Co Ltd, H1 2017
    Pipeline by Eli Lilly and Company, H1 2017
    Pipeline by Genosco Inc, H1 2017
    Pipeline by H3 Biomedicine Inc, H1 2017
    Pipeline by Incyte Corp, H1 2017
    Pipeline by Ionis Pharmaceuticals Inc, H1 2017
    Pipeline by Johnson & Johnson, H1 2017
    Pipeline by NGM Biopharmaceuticals Inc, H1 2017
    Pipeline by Novartis AG, H1 2017
    Pipeline by Principia Biopharma Inc, H1 2017
    Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2017
    Pipeline by Vichem Chemie Research Ltd, H1 2017
    Dormant Projects, H1 2017
    Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Amgen Inc
    ArQule Inc
    Astellas Pharma Inc
    AstraZeneca Plc
    Blueprint Medicines Corp
    Bristol-Myers Squibb Company
    Eisai Co Ltd
    Eli Lilly and Company
    Genosco Inc
    H3 Biomedicine Inc
    Incyte Corp
    Ionis Pharmaceuticals Inc
    Johnson & Johnson
    NGM Biopharmaceuticals Inc
    Novartis AG
    Principia Biopharma Inc
    Tasly Pharmaceutical Group Co Ltd
    Vichem Chemie Research Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//fibroblast-growth-factor-receptor-4-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//fibroblast-growth-factor-receptor-4-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//fibroblast-growth-factor-receptor-4-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments